SLC9A1 and diabetes mellitus: Although SOTA inhibits SGLT1, the similarly confirmed cardioprotective effects of the two drugs suggest that NHE1 inhibition rather than SGLT1 inhibition is the main mechanism behind this effect in the DM-HFrEF zebrafish model.